Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Augen Therapeutics
- Ownership
- Private
- Development stage
- Preclinical
01
Overview
Developing oral IDO inhibitors that appear to prevent blood vessel damage in the eye associated with diabetes
- Therapeutic areas
- Ophthalmology
- Modalities
- Small molecules (IDO inhibitors)
- Industry
- Biotech
02
Partnerships
Lankenau Institute for Medical Research (LIMR)
Beyond the preview
Go deeper on Augen Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Augen Therapeutics.